
In TRAVERSE, monitored testosterone gel was noninferior to placebo for cardiovascular death, nonfatal heart attack, or nonfatal stroke in men with hypogonadism and cardiovascular disease or elevated risk. That does not establish heart protection or universal safety. Blood-pressure increases and additional safety findings remain relevant, and results should not be generalized to high-dose anabolic use.12
Key points
- TRAVERSE primary events occurred in 7.0% versus 7.3%.1
- Noninferiority is not evidence of cardiovascular prevention.1
- FDA blood-pressure warnings remain relevant alongside changed cardiovascular language.2
Does testosterone treatment increase heart attacks or strokes?
The best large randomized evidence did not find a higher rate of the combined endpoint of cardiovascular death, nonfatal heart attack, or nonfatal stroke with monitored testosterone gel compared with placebo in men with hypogonadism and cardiovascular disease or elevated risk. The TRAVERSE result is reassuring within that setting, but it is not proof that testosterone prevents heart disease or is risk-free. 1
The distinction matters because cardiovascular health includes more than that combined endpoint. Blood pressure, rhythm disorders, blood clots, and individual treatment circumstances still need attention. Results from replacement treatment cannot simply be applied to high-dose anabolic use or to men without an appropriate diagnosis.
What did TRAVERSE actually test?
TRAVERSE enrolled more than 5,200 men aged 45-80 with symptoms, two fasting testosterone results below 300 ng/dL, and established cardiovascular disease or elevated risk. Participants used testosterone gel or placebo with protocol-directed adjustment and monitoring. The mean treatment duration was about 22 months and mean follow-up about 33 months. 1
The primary cardiovascular outcome occurred in 7.0% of testosterone participants and 7.3% of placebo participants. The hazard ratio was 0.96, with a 95% confidence interval of 0.78-1.17. The study met its prespecified noninferiority criterion. 1
Those numbers support the conclusion that the trial did not detect an unacceptable increase in the defined endpoint under its design. They do not show a statistically established protective effect, and the confidence interval is compatible with a range of smaller differences. Finite follow-up also cannot establish lifetime safety.

What does noninferior mean for a treatment decision?
A noninferiority trial tests whether a treatment is worse than its comparator by more than a prespecified margin. Passing that test is different from proving that the two are identical, that every adverse event is equally common, or that treatment is beneficial for cardiovascular prevention.
For a person with a real indication for testosterone, the trial helps estimate one part of the risk-benefit discussion. It does not create that indication. The decision still includes the symptoms being treated, alternative explanations, contraindications, fertility plans, and monitoring burden.
TRAVERSE principally addressed a concern about major cardiovascular events during replacement therapy. Using it as evidence that more testosterone is better for the heart asks the study to answer a different question.
What risks remain relevant after the primary result?
TRAVERSE reported higher incidences of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group. These were additional safety findings rather than the composite primary endpoint, and they should be considered without implying that every event type has an equally precise risk estimate. 1
Blood pressure is another separate issue. FDA's 2025 review of ambulatory blood-pressure studies led to requirements for blood-pressure information and warnings across testosterone products. The agency simultaneously directed removal of boxed-warning language concerning increased adverse cardiovascular outcomes after reviewing TRAVERSE. 2
A favorable headline about heart attacks and strokes therefore does not remove the need to monitor blood pressure or review clot and rhythm history. The side-effects guide covers the broader treatment picture, while hematocrit monitoring addresses another blood-related consideration.
Which cardiovascular question does each source answer?
Several types of evidence appear in discussions of testosterone and the heart. They should be kept in view together without being treated as equivalent. A scan may raise a mechanistic concern; a clinical-events trial can test whether a specified harm occurs more often; a regulatory communication records how an agency is updating prescribing information.
| Source | Question addressed | Main limitation |
|---|---|---|
| TRAVERSE randomized trial | Does monitored gel exceed the prespecified risk margin for major cardiovascular events? 1 | Specific population, formulation, monitoring and finite follow-up. |
| TTrials coronary CT study | Does noncalcified plaque volume change over one year? 3 | Surrogate endpoint; too small for clinical events. |
| FDA blood-pressure review | Do products require pressure-related prescribing information? 2 | Does not make all formulations identical. |
| June 2026 FDA/HHS communication | Which further labeling changes were requested? 45 | Request does not confirm every product label is already updated. |

Why did an earlier study find more coronary plaque?
A small cardiovascular substudy of the Testosterone Trials found a greater increase in noncalcified coronary plaque volume with testosterone gel than placebo over one year in older men with low testosterone. It used coronary CT imaging and was not large enough to determine differences in heart attacks or strokes. 3
The plaque result and TRAVERSE are not a direct contradiction because they measured different outcomes in different studies. Imaging is useful, but plaque volume is a surrogate. Clinical events depend on additional processes that a scan does not fully capture.
The larger clinical-events trial provides more direct evidence about its specific safety question, while the imaging finding helped explain why longer outcome research was needed. Neither study demonstrates a reason to start testosterone solely to improve cardiovascular health.
What changed in FDA information through 2026?
FDA's February 2025 communication described changes based on TRAVERSE and blood-pressure studies: removal of the boxed-warning language on adverse cardiovascular outcomes, inclusion of trial results, and blood-pressure warnings. 2
FDA's current Testosterone Information page also records requested prescribing-information updates in June 2026 concerning the limitation of use for age-related hypogonadism and prostate-related safety information. The HHS announcement describes these as requested or proposed label changes. 45
An agency's request is not the same as confirming that every individual product label has already been revised. The current prescribing information for the actual product remains relevant. None of these announcements changes the underlying distinction between treatment of a diagnosed condition and using testosterone as a heart-protection strategy. Readers should also avoid relying on older summaries that present superseded boxed-warning wording as current.
What should a cardiovascular review before TRT include?
A clinician should review existing cardiovascular disease, recent events, blood pressure, clotting history, symptoms, and conditions that may change treatment suitability. The Endocrine Society guideline advises against starting testosterone in circumstances including uncontrolled heart failure, a heart attack or stroke within the preceding six months, and thrombophilia. 6
Someone with chest discomfort, sudden shortness of breath, signs of stroke, or a suspected clot needs prompt or emergency assessment according to the symptoms. These are not situations to manage by waiting for the next routine testosterone level.
During ongoing treatment, the practical question is whether the intended benefit remains meaningful and the monitoring plan is being followed. The article on monitoring tests explains why normalization of testosterone alone is insufficient. Cardiovascular risk reduction still follows its own plan, including management of blood pressure, lipids, diabetes, smoking, and other relevant factors.
Common questions
Does TRAVERSE prove TRT is good for the heart?
No. It tested a safety question and met a noninferiority criterion. It did not establish testosterone as a treatment to prevent cardiovascular disease.1
Can the gel result be applied to every testosterone regimen?
Did FDA remove every testosterone warning?
Does a low starting testosterone level remove the need to check blood pressure?
No. A diagnosis can justify considering treatment, but it does not remove treatment-related monitoring. FDA required blood-pressure information after reviewing ambulatory monitoring studies, so pressure remains relevant even when the initial testosterone result is clearly low.2
References
- 1.Lincoff et al. Cardiovascular Safety of Testosterone-Replacement Therapy. NEJM. 2023.
- 2.FDA. FDA issues class-wide labeling changes for testosterone products. February 28, 2025.
- 3.Budoff et al. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. JAMA. 2017.
- 4.FDA. Testosterone Information.
- 5.HHS. HHS Announces Requested Updates to Testosterone Therapy Product Labels. June 18, 2026.
- 6.Bhasin et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. JCEM. 2018.
This article is for general education, not medical advice, diagnosis or a treatment recommendation. A licensed clinician can interpret the evidence in the context of your symptoms, tests, medicines and fertility plans.